Limited Evidence of Benefit for Medical Cannabinoids in Children

This article originally appeared here.
Share this content:
Limited Evidence of Benefit for Medical Cannabinoids in Children
Limited Evidence of Benefit for Medical Cannabinoids in Children

MONDAY, Oct. 23, 2017 (HealthDay News) -- The strongest evidence for benefit of cannabinoids in children is for chemotherapy-induced nausea and vomiting, with more research needed to assess its role as a medical treatment, according to a review published online Oct. 23 in Pediatrics.

Shane Shucheng Wong, M.D., and Timothy E. Wilens, M.D., from Massachusetts General Hospital in Boston, conducted a systematic review to examine the evidence base of cannabinoids as a medical treatment in children and adolescents. Twenty-one articles that met inclusion criteria were identified; these articles described 22 studies with 795 participants.

The researchers found that the strongest evidence of benefit was seen for chemotherapy-induced nausea and vomiting, with increasing evidence of benefit seen for epilepsy. The evidence was insufficient to support cannabinoid use for spasticity, neuropathic pain, post-traumatic stress disorder, and Tourette syndrome. There was variation in the methodological quality of studies, with most lacking control groups, limited by small size, and not designed to test for the statistical significance of outcomes. The cannabinoid composition and dosage were heterogeneous among studies, and long-term follow-up was lacking.

"Additional research is needed to evaluate the potential role of medical cannabinoids in children and adolescents, especially given increasing accessibility from state legalization and potential psychiatric and neurocognitive adverse effects identified from studies of recreational cannabis use," the authors write.

Abstract
Full Text (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!

Already a member?

Sign In Now »

Drug Lookup

Browse drugs by: BrandGenericDisease

Trending Activities

All Professions


Sign up for myCME e-newsletters


More in Home

FDA OKs Nucala for Eosinophilic Granulomatosis With Polyangiitis

FDA OKs Nucala for Eosinophilic Granulomatosis With Polyangiitis

First drug to be approved for rare autoimmune disease that leads to vasculitis

Findings Support Individualized Glycemic Control in T2DM

Findings Support Individualized Glycemic Control in T2DM

Approach saved $13,547/patient vs uniform intensive control, with lower medication costs

Atherosclerosis ID'd in Many Without CV Risk Factors

Atherosclerosis ID'd in Many Without CV Risk Factors

LDL-C independently associated with the presence and extent of atherosclerosis

is free, fast, and customized just for you!

Already a member?

Sign In Now »